Dr. Magliocco on Analyzing the Genome of Melanoma Tumors

Anthony M. Magliocco, MD
Published: Wednesday, Oct 30, 2013

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.

Although physicians can now do thorough analyses of the genome, certain tumors, including melanoma tumors, have high mutational loads. This makes it difficult to determine which mutations cause the tumors and which mutations are “passenger mutations,” Magliocco says.

Magliocco speculates that melanoma tumors have more mutations because of sun exposure or mechanisms of DNA repair that cause tumors to acquire more mutations.

In order to determine if the mutations are significant or not, Magliocco says, a molecular biologist looks to see if the mutations occur on an important gene, the mutation is impacting a function of the protein, or if the mutation biologically makes sense to cause the tumor to grow.

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.

Although physicians can now do thorough analyses of the genome, certain tumors, including melanoma tumors, have high mutational loads. This makes it difficult to determine which mutations cause the tumors and which mutations are “passenger mutations,” Magliocco says.

Magliocco speculates that melanoma tumors have more mutations because of sun exposure or mechanisms of DNA repair that cause tumors to acquire more mutations.

In order to determine if the mutations are significant or not, Magliocco says, a molecular biologist looks to see if the mutations occur on an important gene, the mutation is impacting a function of the protein, or if the mutation biologically makes sense to cause the tumor to grow.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x